Related Experiment Video

Updated: Jul 16, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction

J D Lickliter1, J Cox, J McCarron

  • 1Clive Berghofer Cancer Research Centre, Queensland Institute of Medical Research, Herston, Queensland 4029, Australia. Jason_Lickliter@health.qld.gov.au

British Journal of Cancer
|February 22, 2007
PubMed

Insights

Bcl-2 inhibitors enhance anticancer immune responses by overcoming tumor cell resistance to apoptosis. This approach sensitizes cancer cells to immune-mediated killing, improving therapeutic potential.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Anticancer immune cell cytotoxicity relies on target cell apoptosis.
  • The antiapoptotic protein Bcl-2 frequently blocks immune-mediated cancer cell death.
  • Overcoming Bcl-2-mediated resistance is crucial for enhancing immune responses against cancer.

Purpose of the Study:

  • To investigate if Bcl-2 inhibitors can enhance anticancer immune responses.
  • To evaluate the efficacy of Bcl-2 inhibitors in overcoming apoptosis resistance in cancer cells.
  • To explore the mechanisms by which Bcl-2 inhibition potentiates immune-mediated tumor cell killing.

Main Methods:

  • Coincubation of natural killer T (NKT) cells with U937 lymphoma cells and cytotoxic T-lymphocyte clone 1H3 with A02 melanoma cells.
  • Assessment of target cell apoptosis using flow cytometry with annexin-V-FITC and 7-AAD staining.
  • Evaluation of cytotoxicity in the presence and absence of Bcl-2 inhibitors (HA14-1 and ABT-737).

Main Results:

  • Bcl-2 inhibitor HA14-1 significantly increased apoptosis in U937 cells upon co-culture with NKT cells.
  • Bcl-2 inhibitor ABT-737 amplified the killing of A02 melanoma cells by cytotoxic T-lymphocytes.
  • Results suggest that sensitization to perforin/granzyme-B mediated killing contributes to enhanced tumor cell death.

Conclusions:

  • Molecular interventions targeting Bcl-2 can overcome apoptosis resistance in cancer cells.
  • Bcl-2 inhibitors enhance the immune destruction of malignant cells.
  • This strategy holds promise for augmenting anticancer immune responses.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...